TELA Bio
TELA
60 hedge funds and large institutions have $139M invested in TELA Bio in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 11 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 19
3.64% less ownership
Funds ownership: 89.23% → 85.59% (-3.6%)
10% less funds holding
Funds holding: 67 → 60 (-7)
21% less capital invested
Capital invested by funds: $175M → $139M (-$36M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.92M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.71M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.76M |
| 4 |
PCMI
Paradigm Capital Management Inc
Albany,
New York
|
+$1.61M |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$722K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$6M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.2M |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$3.86M |
| 4 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$3.79M |
| 5 |
PVI
Pura Vida Investments
New York
|
-$2.7M |
TELA Hedge Fund Activity: Q4 2023 in Review
60 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in TELA Bio (TELA) for Q4 2023, worth a combined $139M — down 21% from $175M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TELA and 5 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 27 added.
The largest buyer was UBS Group, adding an estimated $3.92M. The largest seller was Opaleye Management, exiting entirely with an estimated $6M sold.
- 60 institutional investors held TELA Bio (TELA) as of Q4 2023, down from 67 in Q3 2023.
- Funds reported $139M of TELA Bio stock for Q4 2023, down 21% quarter-over-quarter.
- 5 funds opened new TELA Bio positions in Q4 2023 and 11 closed out, a net change of -6 holders.
- The largest TELA Bio buyer in Q4 2023 was UBS Group, an estimated $3.92M added.
- The largest TELA Bio seller in Q4 2023 was Opaleye Management, an estimated $6M sold.
Based on aggregated 13F filings for Q4 2023.